Black Diamond Therapeutics (Nasdaq:BDTX) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

BDTX Stoklara Genel Bakış

BDTX temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 7.7% oranında düşmesi öngörülüyor

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

+ 1 daha fazla risk

Black Diamond Therapeutics, Inc. Rakipler

Pyxis Oncology

NasdaqGS:PYXS

US$210.4m

Inhibrx Biosciences

NasdaqGS:INBX

US$213.7m

Spectrum Pharmaceuticals

NasdaqCM:SPPI

US$209.9m

Cabaletta Bio

NasdaqGS:CABA

US$208.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Black Diamond Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$3.75
52 Haftanın En Yüksek Seviyesi	US$7.66
52 Haftanın En Düşük Seviyesi	US$1.62
Beta	2.48
11 Aylık Değişim	-30.56%
3 Aylık Değişim	-14.19%
1 Yıllık Değişim	43.13%
33 Yıllık Değişim	-51.04%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-90.50%

Son Haberler & Güncellemeler

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Jun 27

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

May 21

Recent updates

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Jun 27

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

May 21

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Jan 31

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Jan 12

Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

Oct 26

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

May 05

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Jan 16

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Oct 02

Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

Jul 02

We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

Jan 16

We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely

Jun 11

Black Diamond Therapeutics EPS misses by $0.16

May 07

We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Feb 26

What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition

Jan 05

Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?

Dec 01

Hissedar Getirileri

	BDTX	US Biotechs	US Pazar
7D	-11.3%	-0.5%	0.4%
1Y	43.1%	18.3%	32.6%

Getiri vs. Endüstri: BDTX geçen yıl % 22.1 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: BDTX geçen yıl % 34.1 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is BDTX's price volatile compared to industry and market?
BDTX volatility
BDTX Average Weekly Movement	12.8%
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: BDTX hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: BDTX 'nin haftalık oynaklığı ( 13% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2014	54	Mark Velleca	www.blackdiamondtherapeutics.com

Klinik aşamada bir onkoloji ilaç şirketi olan Black Diamond Therapeutics, Inc. genetik olarak tanımlanmış tümörleri olan hastalar için MasterKey tedavilerinin keşfi ve geliştirilmesine odaklanmaktadır. Şirketin öncü ürün adayı, epidermal büyüme faktörü reseptörü mutant küçük hücreli dışı akciğer kanserinin tedavisi için faz 2 klinik çalışmasında ve glioblastoma tedavisi için faz 1 klinik çalışmasında olan, beyin penetrant epidermal büyüme faktörü reseptörü MasterKey inhibitörü olan BDTX-1535'tir. Ayrıca, faz 1 klinik çalışmasında olan solid tümörlerde KRAS, NRAS ve BRAF değişikliklerini hedefleyen bir beyin-penetrant RAF MasterKey inhibitörü olan BDTX-4933'ü geliştirmektedir.

Black Diamond Therapeutics, Inc. Temel Bilgiler Özeti

Black Diamond Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
BDTX temel i̇stati̇sti̇kler
Piyasa değeri	US$211.89m
Kazançlar(TTM)	-US$80.55m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-2.6x

F/K Oranı

BDTX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
BDTX gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$80.55m
Kazançlar	-US$80.55m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.43
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

BDTX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

BDTX Stoklara Genel Bakış

Ödüller

Risk Analizi

Black Diamond Therapeutics, Inc. Rakipler

NasdaqGS:PYXS

US$210.4m

NasdaqGS:INBX

US$213.7m

NasdaqCM:SPPI

US$209.9m

NasdaqGS:CABA

US$208.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Black Diamond Therapeutics, Inc. Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients

Price target increased by 8.1% to US$13.83

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Co-Founder & Director notifies of intention to sell stock

New major risk - Shareholder dilution

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

Recent updates

Black Diamond Therapeutics, Inc. Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients

Price target increased by 8.1% to US$13.83

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Co-Founder & Director notifies of intention to sell stock

New major risk - Shareholder dilution

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

Black Diamond Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Price target increased by 9.4% to US$11.60

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Black Diamond Therapeutics, Inc. Announces Resignation of Rajeev Shah from Board of Directors, Including as A Member of the Audit Committee of the Board

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Black Diamond Therapeutics, Inc. Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

New minor risk - Share price stability

Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

New minor risk - Market cap size

Black Diamond Therapeutics, Inc. Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Black Diamond Therapeutics, Inc. Announces Chief Executive Officer Changes

Black Diamond Therapeutics, Inc. Doses First Patients in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer

New major risk - Financial position

New minor risk - Shareholder dilution

New major risk - Share price stability

Black Diamond Therapeutics, Inc. Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

Price target increased by 38% to US$9.33

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Key Executive recently bought US$72k worth of stock

Black Diamond Therapeutics, Inc. Announces Changes to Board of Directors

High number of new directors

Black Diamond Therapeutics, Inc. Appoints as Melanie Morrison as Senior Vice President, Development Operations

Black Diamond Therapeutics, Inc. Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Price target decreased to US$7.00

Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

Key Executive recently bought US$61k worth of stock

Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) dropped from Russell 2500 Index

Black Diamond Therapeutics Appoints Sergey Yurasov as Chief Medical Officer

High number of new directors

Black Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based on its Proprietary MAP Discovery Engine

Price target decreased to US$8.00

High number of new directors

Black Diamond Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of BDTX-1535

Black Diamond Therapeutics, Inc. Announces Board Changes

Price target decreased to US$21.60

Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People Officer

We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung Cancer

Executive Officer Thomas Leggett has left the company

Price target decreased to US$42.83

Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) dropped from Russell 2500 Growth Index

We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely

Black Diamond Therapeutics, Inc. Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Advanced Solid Tumors Harboring EGFR or HER2 Alterations

COO & General Counsel exercised options and sold US$99k worth of stock

Black Diamond Therapeutics EPS misses by $0.16

COO & General Counsel exercised options and sold US$89k worth of stock

COO & General Counsel exercised options and sold US$94k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Black Diamond Therapeutics Announces Pre-Clinical Data Presentations on New Programs Targeting BRAF and FGFR at ESMO TAT Virtual Congress 2021

We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

COO & General Counsel exercised options and sold US$98k worth of stock